Iron deficiency anemia is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalization rates.
While the best way of treating iron deficiency anemia in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anemia or intolerance to oral iron compounds.
Dr Stein and colleagues from Germany compared the efficacy and tolerability of different intravenous iron formulations used to treat iron deficiency anemia in IBD patients in a systematic review and Bayesian network meta-analysis.
In 2016, the researchers systematically searched for studies analysing efficacy and safety of intravenous iron for iron deficiency anemia therapy in IBD.
|Pooled data revealed adverse event rates of 12% for ferric carboxymaltose|
|Alimentary Pharmacology & Therapeutics|
The team's primary outcome was therapy response, defined as hemoglobin normalization or increase ≥2 g/dL.
The research team included 5 randomized, controlled trials were included in a network meta-analysis.
Only ferric carboxymaltose was significantly more effective than oral iron.
Rank probabilities showed ferric carboxymaltose to be most effective, followed by iron sucrose, iron isomaltose and oral iron.
The team found that pooled data from the systematic review revealed adverse event rates of 12%, 15%, 12%, 17% for ferric carboxymaltose, iron sucrose, iron dextran and iron isomaltose, respectively.
The researchers noted that 1 drug-related serious adverse event each was reported for ferric carboxymaltose and iron isomaltoside, and one possibly drug-related serious adverse event for iron sucrose.
Dr Stein's team comments, "Ferric carboxymaltose was the most effective intravenous iron formulation, followed by iron sucrose."
"In addition, ferric carboxymaltose tended to be better tolerated."
"Thus, nanocolloidal IV iron products exhibit differing therapeutic and safety characteristics and are not interchangeable."